Abstract
In this work, we have designed a siRNA-nanoformulation with mesoporous polycaprolactone (hmPCL) for silencing and cancer therapy. Average hollow core size of hmPCL nanocapsules used for nanoformulation is ~ 180 nm with shell thickness of 10-20 nm and mesopore size of ~ 5-10 nm in diameter. Idiosyncratic capsules are biocompatible which has been confirmed with normal lymphocyte, K562 leukaemia cancer cells and on HepG2/EGFP cancer cells. In 1 mg of hmPCL capsules up to 400 ng of siRNA can be loaded. This nanoformulation enables to tune the dose dependent delivery up to ~ 93.25% (373 ng) siRNA during therapy. hmPCL-siRNA nanoformulation mediated siRNA transfection on HepG2 cancer cells has been investigated and exhibited 32% silencing activity within 24 h of post transfection. Obtained results directed us that the hmPCL-siRNA nanoformulation could be an efficient tool in siRNA mediated therapy for knocking down the infected cells.
| Original language | English |
|---|---|
| Pages (from-to) | 579-588 |
| Number of pages | 10 |
| Journal | Nanomedicine: Nanotechnology, Biology, and Medicine |
| Volume | 12 |
| Issue number | 3 |
| DOIs | |
| State | Published - 1 Apr 2016 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2015 Elsevier Inc.
Funding
The authors acknowledge the financial support from the Department of Science and Technology (DST) for Fast-Track Grant for Young Scientist (Ref: SR/FTP/ETA-0079/2011 ) and School of Life Science, University of Hyderabad for cell culture facilities.
| Funders | Funder number |
|---|---|
| Department of Science and Technology, Ministry of Science and Technology, India | SR/FTP/ETA-0079/2011 |
Keywords
- Cancer therapy
- Hollow-mesoporous-PCL
- Nanocapsules
- Nanoformulation
- SiRNA-silencing
